Aratana Therapeutics Inc. (NASDAQ:PETX) has been assigned a consensus recommendation of “Buy” from the nine analysts that are currently covering the stock. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $11.86.
A number of analysts recently commented on the company. Barclays PLC decreased their price target on Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating for the company in a research report on Thursday, August 11th. Credit Suisse Group AG reissued a “buy” rating and set a $11.00 price objective on shares of Aratana Therapeutics in a report on Wednesday, August 10th. Jefferies Group started coverage on Aratana Therapeutics in a report on Friday, August 19th. They set a “buy” rating and a $13.00 price objective for the company. William Blair reissued an “outperform” rating on shares of Aratana Therapeutics in a report on Wednesday, August 17th. Finally, Lake Street Capital reissued a “buy” rating and set a $15.00 price objective on shares of Aratana Therapeutics in a report on Tuesday, September 6th.
In related news, insider Peter Steven St sold 50,000 shares of the stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $9.25, for a total value of $462,500.00. Following the sale, the insider now owns 642,793 shares in the company, valued at $5,945,835.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Craig A. Tooman sold 30,000 shares of the stock in a transaction on Friday, September 9th. The stock was sold at an average price of $9.25, for a total value of $277,500.00. Following the completion of the sale, the insider now owns 72,424 shares in the company, valued at approximately $669,922. The disclosure for this sale can be found here. 6.70% of the stock is owned by insiders.
Several large investors have recently modified their holdings of PETX. Metropolitan Life Insurance Co. NY acquired a new stake in shares of Aratana Therapeutics during the second quarter worth about $162,000. First Light Asset Management LLC increased its stake in shares of Aratana Therapeutics by 52.9% in the second quarter. First Light Asset Management LLC now owns 684,921 shares of the biopharmaceutical company’s stock worth $4,329,000 after buying an additional 236,915 shares during the period. A.R.T. Advisors LLC increased its stake in shares of Aratana Therapeutics by 81.5% in the second quarter. A.R.T. Advisors LLC now owns 71,515 shares of the biopharmaceutical company’s stock worth $451,000 after buying an additional 32,111 shares during the period. Bridgeway Capital Management Inc. increased its stake in shares of Aratana Therapeutics by 85.1% in the second quarter. Bridgeway Capital Management Inc. now owns 86,983 shares of the biopharmaceutical company’s stock worth $550,000 after buying an additional 40,000 shares during the period. Finally, Parametric Portfolio Associates LLC increased its stake in shares of Aratana Therapeutics by 16.6% in the second quarter. Parametric Portfolio Associates LLC now owns 27,958 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 3,989 shares during the period. Institutional investors own 85.56% of the company’s stock.
Aratana Therapeutics (NASDAQ:PETX) opened at 9.13 on Monday. Aratana Therapeutics has a 52 week low of $2.56 and a 52 week high of $17.63. The company’s market cap is $323.34 million. The stock has a 50 day moving average price of $9.05 and a 200 day moving average price of $6.93.
Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.61 EPS for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.37. The company earned $38.05 million during the quarter, compared to the consensus estimate of $15.14 million. Aratana Therapeutics had a negative return on equity of 17.53% and a negative net margin of 166.67%. During the same period last year, the business posted ($0.23) earnings per share. On average, equities analysts forecast that Aratana Therapeutics will post ($0.77) earnings per share for the current year.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with our FREE daily email newsletter.
